BioFactura is on Course to Become a Global Leader in Biosimilar Development

Published on : Published by : Alex Keown

Since the approval of the first biosimilar drug in the United States six years ago, the market has rapidly expanded and is expected to grow to approximately $23 billion in the U.S. by 2027. And Maryland’s BioFactura anticipates it will be one of the companies at the forefront of this revolution of new medications.

5 Questions with Nivedita Hegdekar, Scientific Writer, and Communications Co-Chair for the Women in Bio Capital Region Chapter

Published on : Published by : Andy Eckert

Nivedita ‘Niv’ Hegdekar is a graduate student at the University of Maryland, Baltimore pursuing a dual degree in biomedical sciences and patent law. Prior to joining her PhD program, she obtained her degree in pharmacy and pharmaceutical sciences from the prestigious Institute of Chemical Technology, Mumbai, India.

5 Questions with Natalie McKinney, Industry Programs Director, Biologics, US Pharmacopeia

Published on : Published by : Andy Eckert

Natalie McKinney is a marketing strategy leader with 15+ years of experience in life sciences and technology organizations. She uses data-driven, customer-centric approaches to gain a deep understanding of dynamic customer needs and drivers. She enjoys leveraging internal and external relationships to build a holistic customer view and gains alignment on high-impact, right-sized product and marketing investments that are timed appropriately for the market.